Recursion Pharmaceuticals Puts Strength on Full Display [TheStreet.com]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: TheStreet.com
Recursion Pharmaceuticals ( ) recently raised $150 million in gross proceeds from a private placement of common stock, including half from a single fund that has never before invested in the company. A private placement means all shares were sold directly to investment funds rather than offered to the public. Such transactions typically occur at more favorable prices than public offerings of common stock. The new capital will pad a that held about $454 million in cash at the end of June, which will be burned quickly by the company's ambitious drug development strategy. For example, the drug developer has initiated four new clinical trials in 2022 alone. It's also a promising sign of strength for investors, although long-term performance will be driven by execution and clinical trial data. Mapping Biology to Discover New Drugs Recursion Pharmaceuticals is a technology-enabled drug developer. It's part of an emerging field that utilizes supercomputers, machine learning, and automate
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Where Will Recursion Pharmaceuticals Be in 5 Years? [Yahoo! Finance]Yahoo! Finance
- Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerGlobeNewswire
- Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. [Yahoo! Finance]Yahoo! Finance
- Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate [Seeking Alpha]Seeking Alpha
RXRX
Earnings
- 2/27/24 - Beat
RXRX
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEF
- 4/23/24 - Form DEFA14A
- RXRX's page on the SEC website